Great f.y.i. Get hooked here!
How are you feeling today? Keep up to date on news and stories related to healthcare here!
The Navajo Nation on Monday will reinstate a stay-at-home lockdown for the entire reservation while closing tribal offices and requiring new closures and safety measures for businesses due to rising COVID-19 cases. — FOX News
The school system, the nation’s largest, has had strikingly few virus cases. Even so, the mayor may end in-person classes because the city’s overall rate is surging. — New York Times: Top Stories
• Metagenomi is a genomic medicines company pioneering precision gene editing systems to advance curative therapies for oncology and genetic diseases • Proprietary and wholly owned gene editing platform offers the potential to expand the range of treatable diseases and to improve patient
Staten Island has bristled at coronavirus restrictions, but now has the highest positive test rate in the New York City. — NYT: Top Stories
Results for our CD19-targeted CAR T cell therapy lisocabtagene maraleucel (liso-cel) in patients with heavily pretreated mantle cell lymphoma and relapsed/refractory chronic lymphocytic leukemia Data showcasing BCMA-targeted CAR T cell therapy idecabtagene vicleucel (ide-cel), including updated results from the Phase 1 CRB-401
LENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus Sunitinib Results of Investigational Phase 3 KEYNOTE-581/CLEAR Trial (Study 307) to be Presented at Upcoming Medical Meeting KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK): KEYTRUDA®
Pfizer announced positive early results from its coronavirus vaccine trial, cementing the lead in a frenzied global race that has unfolded at record-breaking speed. Wall Street was set to open higher following gains in global markets on the first day of trading
Deucravacitinib, the first and only novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor in clinical studies across multiple immune-mediated diseases, showed significantly greater ACR 20 responses compared to placebo at 16 weeks and met all key secondary endpoints Deucravacitinib was well-tolerated with
Approval based on Phase 3 CheckMate -9LA trial results showing superior overall survival in patients with metastatic non-small cell lung cancer, regardless of PD-L1 expression or tumor histologies European Commission decision marks the first time a dual immunotherapy with limited chemotherapy is